These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 34464398)

  • 1. To what extent are the antimalarial markets in African countries ready for a transition to triple artemisinin-based combination therapies?
    de Haan F; Bolarinwa OA; Guissou R; Tou F; Tindana P; Boon WPC; Moors EHM; Cheah PY; Dhorda M; Dondorp AM; Ouedraogo JB; Mokuolu OA; Amaratunga C
    PLoS One; 2021; 16(8):e0256567. PubMed ID: 34464398
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ethical considerations in deploying triple artemisinin-based combination therapies for malaria: An analysis of stakeholders' perspectives in Burkina Faso and Nigeria.
    Tindana P; Guissou R; Bolarinwa OA; Tou F; de Haan F; Dhorda M; Dondorp AM; Amaratunga C; Mokuolu OA; Ouedraogo JB; Cheah PY
    PLoS One; 2022; 17(9):e0273249. PubMed ID: 36083995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expert perspectives on the introduction of Triple Artemisinin-based Combination Therapies (TACTs) in Southeast Asia: a Delphi study.
    de Haan F; Boon WPC; Amaratunga C; Dondorp AM
    BMC Public Health; 2022 Apr; 22(1):864. PubMed ID: 35490212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of anti-malarial markets on artemisinin resistance: perspectives from Burkina Faso.
    Guissou RM; Amaratunga C; de Haan F; Tou F; Cheah PY; Yerbanga RS; Moors EHM; Dhorda M; Tindana P; Boon WPC; Dondorp AM; Ouédraogo JB
    Malar J; 2023 Sep; 22(1):269. PubMed ID: 37705004
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ethical, Regulatory and Market related aspects of Deploying Triple Artemisinin-Based Combination Therapies for Malaria treatment in Africa: A study protocol.
    Tindana P; de Haan F; Mokuolu OA; Guissou R; Bolarinwa OA; Ouedraogo JB; Tou F; Boon WPC; Moors EHM; Dondorp AM; Dhorda M; Amaratunga C; Cheah PY
    Wellcome Open Res; 2021; 6():75. PubMed ID: 34458588
    [No Abstract]   [Full Text] [Related]  

  • 7. Subsidising artemisinin-based combination therapy in the private retail sector.
    Opiyo N; Yamey G; Garner P
    Cochrane Database Syst Rev; 2016 Mar; 3(3):CD009926. PubMed ID: 26954551
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Combined antimalarial therapy using artemisinin].
    Majori G
    Parassitologia; 2004 Jun; 46(1-2):85-7. PubMed ID: 15305693
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Got ACTs? Availability, price, market share and provider knowledge of anti-malarial medicines in public and private sector outlets in six malaria-endemic countries.
    O'Connell KA; Gatakaa H; Poyer S; Njogu J; Evance I; Munroe E; Solomon T; Goodman C; Hanson K; Zinsou C; Akulayi L; Raharinjatovo J; Arogundade E; Buyungo P; Mpasela F; Adjibabi CB; Agbango JA; Ramarosandratana BF; Coker B; Rubahika D; Hamainza B; Chapman S; Shewchuk T; Chavasse D
    Malar J; 2011 Oct; 10():326. PubMed ID: 22039838
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patients with positive malaria tests not given artemisinin-based combination therapies: a research synthesis describing under-prescription of antimalarial medicines in Africa.
    O'Boyle S; Bruxvoort KJ; Ansah EK; Burchett HED; Chandler CIR; Clarke SE; Goodman C; Mbacham W; Mbonye AK; Onwujekwe OE; Staedke SG; Wiseman VL; Whitty CJM; Hopkins H
    BMC Med; 2020 Jan; 18(1):17. PubMed ID: 31996199
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prices and mark-ups on antimalarials: evidence from nationally representative studies in six malaria-endemic countries.
    Palafox B; Patouillard E; Tougher S; Goodman C; Hanson K; Kleinschmidt I; Torres Rueda S; Kiefer S; O'Connell K; Zinsou C; Phok S; Akulayi L; Arogundade E; Buyungo P; Mpasela F; Poyer S; Chavasse D
    Health Policy Plan; 2016 Mar; 31(2):148-60. PubMed ID: 25944705
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Stakeholder perceptions on the deployment of multiple first-line therapies for uncomplicated malaria: a qualitative study in the health district of Kaya, Burkina Faso.
    Hien D; Kaboré JMT; Siribié M; Soulama I; Barry N; Baguiya A; Tiono AB; Tchouatieu AM; Sirima SB
    Malar J; 2022 Jun; 21(1):202. PubMed ID: 35761273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Artemisinin-based combination therapies (ACTs): best hope for malaria treatment but inaccessible to the needy!
    Mutabingwa TK
    Acta Trop; 2005 Sep; 95(3):305-15. PubMed ID: 16098946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment-seeking patterns for malaria in pharmacies in five sub-Saharan African countries.
    Ladner J; Davis B; Audureau E; Saba J
    Malar J; 2017 Aug; 16(1):353. PubMed ID: 28851358
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preventing antimalarial drug resistance with triple artemisinin-based combination therapies.
    Nguyen TD; Gao B; Amaratunga C; Dhorda M; Tran TN; White NJ; Dondorp AM; Boni MF; Aguas R
    Nat Commun; 2023 Jul; 14(1):4568. PubMed ID: 37516752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do anti-malarials in Africa meet quality standards? The market penetration of non quality-assured artemisinin combination therapy in eight African countries.
    ; Newton PN; Hanson K; Goodman C
    Malar J; 2017 May; 16(1):204. PubMed ID: 28539125
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of the Affordable Medicines Facility--malaria (AMFm) on the availability, price, and market share of quality-assured artemisinin-based combination therapies in seven countries: a before-and-after analysis of outlet survey data.
    Tougher S; ; Ye Y; Amuasi JH; Kourgueni IA; Thomson R; Goodman C; Mann AG; Ren R; Willey BA; Adegoke CA; Amin A; Ansong D; Bruxvoort K; Diallo DA; Diap G; Festo C; Johanes B; Juma E; Kalolella A; Malam O; Mberu B; Ndiaye S; Nguah SB; Seydou M; Taylor M; Rueda ST; Wamukoya M; Arnold F; Hanson K
    Lancet; 2012 Dec; 380(9857):1916-26. PubMed ID: 23122217
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adherence to malaria diagnosis and treatment guidelines among healthcare workers in Ogun State, Nigeria.
    Bamiselu OF; Ajayi I; Fawole O; Dairo D; Ajumobi O; Oladimeji A; Steven Y
    BMC Public Health; 2016 Aug; 16(1):828. PubMed ID: 27538947
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Understanding private sector antimalarial distribution chains: a cross-sectional mixed methods study in six malaria-endemic countries.
    Palafox B; Patouillard E; Tougher S; Goodman C; Hanson K; Kleinschmidt I; Rueda ST; Kiefer S; O'Connell KA; Zinsou C; Phok S; Akulayi L; Arogundade E; Buyungo P; Mpasela F; Chavasse D
    PLoS One; 2014; 9(4):e93763. PubMed ID: 24699934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Misuse of Artemisinin Combination Therapies by Clients of Medicine Retailers Suspected to Have Malaria Without Prior Parasitological Confirmation in Nigeria.
    Nwokolo E; Ujuju C; Anyanti J; Isiguzo C; Udoye I; BongosIkwue E; Ezire O; Raji M; Oyibo WA
    Int J Health Policy Manag; 2018 Jun; 7(6):542-548. PubMed ID: 29935131
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.